Quarterly report pursuant to Section 13 or 15(d)

Share Capital - Summary of Potentially Dilutive Securities (Detail)

v3.22.2.2
Share Capital - Summary of Potentially Dilutive Securities (Detail) - shares
 9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]    
Common share options 7,877 10,504
Restricted stock units 341,984
Warrants 22,640
Secured notes 46,458
Debentures 10,135
MPX dilutive instruments [1] 408
Total 349,861 90,145
[1] Prior to the acquisition of MPX Bioceutical Corporation (“MPX”) on February 5, 2019 (the “MPX Acquisition”), MPX had instruments outstanding that were potentially dilutive and as a result of the MPX Acquisition, the Company assumed certain of these instruments which were settled on August 18, 2022 by issuing 408 common shares.